Crohn Disease
765
134
173
271
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
73 trials with published results (10%)
Research Maturity
271 completed trials (35% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.8%
75 terminated out of 765 trials
78.3%
-8.2% vs benchmark
15%
112 trials in Phase 3/4
27%
73 of 271 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 271 completed trials
Clinical Trials (765)
Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
Precise Infliximab Exposure and Pharmacodynamic Control
Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
A Smartphone Application for Added Psychological Wellbeing in Crohn's Disease
Study of Imaginomics Predicting Early Surgical Rates in Crohn's Disease
Standardized Microbiota Transplant Therapy in Crohn's Disease
Quantify the Value of Transmural Inflammation in the Treatment of Crohn's Disease With Ustekinumab:an Analysis Based on Imaging Science
Adjunctive Treatment With Vitamin D3 in Patients With Active IBD
Therapeutic Effect of New Biologics in Crohn's Disease
IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
Implementing a Multimodal RCT Intervention to Improve the Transition of Patients With Crohn's Disease From Pediatric to Adult Care
Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
Predictors of Prognosis in IBD Patients
Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group
The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease
Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease
A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Physical Fitness Levels in Children and Adolescents With Chronic Inflammatory Bowel Disease (CIBD): Crohn's Disease, Ulcerative Colitis, Chronic Unclassified Colitis